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Introduction 
 
As hospitalists, we often care for patients who either present with diarrhea or develop diarrhea 
during their hospital visit.  We have learned to think of Clostridium difficile infection (CDI) 
early.  In the United States, administrative data demonstrated significant increases in hospitalized 
patients with CDI beginning in 2001 (1). Discharge diagnosis of CDI more than doubled 
between 2000 and 2009. In 2011, Clostridium difficile was responsible for more than 450,000 
infections and more than 29,000 deaths in the United States (2). Patient outcomes associated with 
hospital-acquired infection include increased mortality, length of stay and rate of discharge to 
long-term care (3). This infection is of particular interest in the healthcare setting, given the risk 
of environmental exposure and healthcare transmission of infection via the spore form of the 
organism.  
  
Case definition 
 
The case definition for Clostridium difficile infection is a patient with a) three or more unformed 
stools within 24 hours, and b) either a positive stool test or diagnosis of pseudomembranous 
colitis.  Patients may be asymptomatic carriers, colonized by C. difficile instead of infected by 
the organism.  In fact, the literature demonstrates “50% or more of hospital patients colonized by 
C. difficile are symptomless carriers…” (1). Transmission is via the fecal-oral route, and C. 
difficile spores are present on the skin and in the environment of colonized and infected patients 
(3). The Centers for Disease Control and Prevention (CDC) define a hospital’s CDI laboratory-
identified (LabID) Event Reporting to the National Healthcare Safety Network (NHSN). 
Definitions distinguish between community-onset infection, when the specimen was collected 
within 3 days of admission; and healthcare facility-onset, when the specimen was collected > 3 
days after admission (4). Estimated time from exposure to development of infection is 2-3 days 
(1). In the NHSN LabID CDI Event Reporting definition, a test is positive when either C. 
difficile toxin A and/or B is positive or toxin-producing C. difficile organism is detected, and the 
stool specimen tested is unformed.  Any subsequent positive test result within two weeks in the 
same facility is considered a duplicate test (4). 
   
Diagnostic methods 
 
Commonly used diagnostic tests include enzyme immunoassay (EIA) tests for toxin A and/or B 
and polymerase chain reaction (PCR) for toxin B detection.  The test in use in our organization, 
University of Missouri Health Care, is the Xpert C. difficile/Epi, a PCR-based test with 
sensitivity 98.7% and specificity 90.9%, as reported in the package insert (5). We typically use 
diagnostic testing to determine a patient’s treatment plan, and to consider isolation and 
environmental disinfection needs.  A positive test does not distinguish between CDI and 
asymptomatic colonization, and positive predictive value is strongly influenced by the pre-test 
probability of infection (6). Patients who have achieved clinical cure of infection with treatment 
will continue to test positive for weeks, and testing stool for clearance is not appropriate or 
necessary (3). 
   
Prevention 
 
Our most effective efforts to prevent Clostridium difficile infection are hand hygiene and 
antimicrobial stewardship.  While C. difficile spores remain infectious in the environment, 
patient exposure to C. difficile in the healthcare setting is primarily attributable to the practices of 
healthcare workers (HCW) (3). Because alcohol does not kill C. difficile spores, healthcare 
workers are advised to use soap and water for hand hygiene after providing care for a patient 
with CDI.  While soap and water do not kill spores, this handwashing practice removes spores 
from HCW hands.  HCW use of gloves is another essential element of hand hygiene in 
protecting patients from hospital-acquired CDI, and gowns complete the contact precautions for 
body substances and environmental contamination (7). In fact, these contact precautions are 
indicated when caring for hospitalized patients with diarrheal illness in advance of the return of 
positive test results.  Other recommended hospital practices are using private rooms and 
dedicated patient care items for infected patients, and environmental disinfection with specific 
products and equipment.  These practices are not recommended for patients who are 
asymptomatic carriers (3). 
   Antibiotics increase patient susceptibility to Clostridium difficile infection by disrupting gut 
flora, and antimicrobial stewardship programs to reduce antibiotic utilization and modify 
antibiotic use patterns are increasingly important.  C. difficile infection risk is highest within the 
first 30 days after antibiotic exposure, but persists as long as 90 days. The particular antibiotic 
class risk for CDI varies by patient population, with published analyses differentiating between 
risk for hospital-acquired and community-acquired infection.  In general, broader spectrum and 
Gram-negative or anaerobic activity increase risk. Clindamycin exposure is associated with 
increased risk (8). Third-generation cephalosporins present the most risk as a class, and 
fluoroquinolones present risk for a particular fluoroquinolone-resistant strain (9). When a patient 
at risk of CDI develops diarrhea, the first tactic in treatment is to discontinue non-CDI antibiotic 
therapy as soon as it is no longer needed for other suspected or proven bacterial infection.   
 
Treatment 
 
Antibiotic therapy specific to CDI should be started when the diagnosis is made, and empiric 
treatment specific to CDI may be appropriate before laboratory confirmation in severe or 
complicated illness.  First-line therapy is metronidazole 500 mg orally, three times daily, with a 
10-14 day duration of therapy, when illness is not severe.  In severe illness, vancomycin is the 
drug of choice, dosed at 125 mg orally, four times daily, with a 10-14 duration of therapy.  In 
severe, complicated CDI, the dose of vancomycin is increased to 500 mg four times daily, 
intravenous metronidazole is added, and vancomycin retention enema is required if patients have 
ileus (1). Surgical consultation is appropriate, particularly when the white cell count and/or 
serum lactate is increasing, as colectomy may be necessary.  Of note, patients with hospital-
acquired infection are at highest risk for recurrence after clinical cure, with estimated first 
recurrence rate of 21% (2). The first recurrence of CDI is usually treated with the same regimen 
as for the initial episode, either with metronidazole or vancomycin, depending on severity. 
Subsequent recurrences should be treated with vancomycin (1). Other treatments with evidence 
of benefit are nitazoxanide, rifaximin and fidaxomicin, probiotics, and fecal bacteriotherapy or 
“fecal transplant” (10). Infectious Diseases and Gastroenterology consultations may be required 
for management of recurrences. 
 
Impact of CDI on hospital finances 
 
Rates of hospital-acquired infection factor in to the Centers for Medicare and Medicaid Services 
(CMS) reporting and payment programs. Reporting hospital-onset CDI to the NHSN is required 
for payment determination as part of the Inpatient Quality Reporting (IQR) program.  In the 
Fiscal Year 2018 Hospital Value Based Purchasing program, 2% of hospital Medicare payment 
is redistributed based on performance in four categories: clinical care, safety, experience of 
care/care coordination, and efficiency/cost reduction.  CDI rates are contained within the safety 
category, as one of seven elements that in aggregate comprise 25% of the performance score 
determining value-based payment.  In the Hospital Acquired Conditions Reduction Program, 
hospitals in the most poorly-performing quartile are penalized 1% of hospital Medicare 
payments.  Eighty-five percent of the performance score is determined by hospital-acquired 
infections, and CDI is one of five in the category (11). Together, these programs provide 
incentives beyond excellent patient care to avoid hospital-onset Clostridium difficile infections, 
through reputational impact of public reporting and financial pressures from payment cuts.   
 
Take-home points 
 
 Clostridium difficile infection (CDI) is increasing in frequency, and is associated with 
mortality and longer length of stay 
 Definition of CDI is diarrhea (3+ unformed stools within 24 hours) and positive stool 
test; patients with clinical cure and colonization may have positive stool test but do not 
have CDI 
 Patients with non-severe CDI should be treated with metronidazole and patients with 
severe CDI should be treated with oral vancomycin.  Either metronidazole or vancomycin 
may be used for recurrent illness, depending on severity; metronidazole should not be 
used beyond the first recurrence 
 Patients with CDI in the hospital require contact isolation, with healthcare workers using 
gown, gloves, and hand hygiene with soap and water to minimize risk of transmission to 
others; isolation is not indicated for colonized patients  
 Antimicrobial stewardship reduces patient risk of CDI 
 Hospital-acquired CDI rates are included in CMS payment reduction programs, with 
financial penalties for poorer performance 
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